ondansetron has been researched along with Liver Diseases in 10 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventeen patients with severe pruritus complicating established chronic liver disease were randomized to receive, double-blind, ondansetron (8 mg) or a placebo orally; each was administered thrice daily for a 4-week period." | 9.12 | Ondansetron and pruritus in chronic liver disease: a controlled study. ( Jones, EA; Molenaar, HA; Oosting, J, 2007) |
| "Recently, the serotonin antagonist ondansetron has been reported to have a positive effect on cholestasis-associated pruritus." | 9.08 | Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. ( Ferenci, P; Kaider, A; Müller, C; Penner, E; Pidlich, J; Pongratz, S; Raderer, M; Scheithauer, W; Schemper, M, 1998) |
| "To examine non-clinical and clinical data relevant to the hypothesis that ondansetron, a 5-HT(3) receptor subtype antagonist, ameliorates pruritus and fatigue in liver disease." | 8.84 | Pruritus and fatigue associated with liver disease: is there a role for ondansetron? ( Jones, EA, 2008) |
| "Seventeen patients with severe pruritus complicating established chronic liver disease were randomized to receive, double-blind, ondansetron (8 mg) or a placebo orally; each was administered thrice daily for a 4-week period." | 5.12 | Ondansetron and pruritus in chronic liver disease: a controlled study. ( Jones, EA; Molenaar, HA; Oosting, J, 2007) |
| "Recently, the serotonin antagonist ondansetron has been reported to have a positive effect on cholestasis-associated pruritus." | 5.08 | Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. ( Ferenci, P; Kaider, A; Müller, C; Penner, E; Pidlich, J; Pongratz, S; Raderer, M; Scheithauer, W; Schemper, M, 1998) |
| "To examine non-clinical and clinical data relevant to the hypothesis that ondansetron, a 5-HT(3) receptor subtype antagonist, ameliorates pruritus and fatigue in liver disease." | 4.84 | Pruritus and fatigue associated with liver disease: is there a role for ondansetron? ( Jones, EA, 2008) |
| " After a single, oral dose of ondansetron, mean absolute bioavailability increased markedly with increased hepatic insufficiency (approaching 100% in the group with severe hepatic impairment versus 66% for control subjects)." | 2.68 | Pharmacokinetics of ondansetron in patients with hepatic insufficiency. ( Carson, SW; Dukes, GE; Figg, WD; Hak, LJ; Hermann, DJ; Lesesne, HR; Powell, JR; Pritchard, JF; Songer, SS, 1996) |
| "Pruritus is often the most troublesome symptom in patients with chronic liver disease, particularly when cholestasis is a prominent feature." | 2.42 | Review article: pruritus in cholestatic and other liver diseases. ( Burroughs, AK; Mancuso, A; Mela, M, 2003) |
| "Ondansetron treatment restored phos-p38 MAPK expression as compared with vehicle-treated haemorrhaged rats." | 1.37 | Ondansetron attenuates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model. ( Liu, FC; Liu, FW; Yu, HP, 2011) |
| "Profound fatigue is a clinically significant complication of chronic liver disease." | 1.33 | Personal view: a potential novel treatment for fatigue complicating chronic liver disease--how should its efficacy be evaluated? ( Jones, EA, 2006) |
| " It is recommended that the dosing frequency of ondansetron be limited to once daily in patients with severe hepatic impairment." | 1.29 | The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. ( Blake, JC; Burroughs, AK; Minton, NA; Palmer, JL, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fitzpatrick, RL | 1 |
| Wittenburg, LA | 1 |
| Hansen, RJ | 1 |
| Gustafson, DL | 1 |
| Quimby, JM | 1 |
| Liu, FC | 1 |
| Liu, FW | 1 |
| Yu, HP | 1 |
| Mela, M | 1 |
| Mancuso, A | 1 |
| Burroughs, AK | 2 |
| Jones, EA | 3 |
| Molenaar, HA | 1 |
| Oosting, J | 1 |
| Hall, TJ | 1 |
| James, PR | 1 |
| Cambridge, G | 1 |
| Blake, JC | 1 |
| Palmer, JL | 1 |
| Minton, NA | 1 |
| Figg, WD | 1 |
| Dukes, GE | 1 |
| Pritchard, JF | 1 |
| Hermann, DJ | 1 |
| Lesesne, HR | 1 |
| Carson, SW | 1 |
| Songer, SS | 1 |
| Powell, JR | 1 |
| Hak, LJ | 1 |
| Müller, C | 1 |
| Pongratz, S | 1 |
| Pidlich, J | 1 |
| Penner, E | 1 |
| Kaider, A | 1 |
| Schemper, M | 1 |
| Raderer, M | 1 |
| Scheithauer, W | 1 |
| Ferenci, P | 1 |
2 reviews available for ondansetron and Liver Diseases
| Article | Year |
|---|---|
Review article: pruritus in cholestatic and other liver diseases.
Topics: Anion Exchange Resins; Antipruritics; Cholagogues and Choleretics; Humans; Liver Diseases; Narcotic | 2003 |
Pruritus and fatigue associated with liver disease: is there a role for ondansetron?
Topics: Animals; Antipruritics; Central Nervous System; Evidence-Based Medicine; Fatigue; Humans; Liver Dise | 2008 |
3 trials available for ondansetron and Liver Diseases
| Article | Year |
|---|---|
Ondansetron and pruritus in chronic liver disease: a controlled study.
Topics: Adolescent; Adult; Aged; Antipruritics; Chronic Disease; Double-Blind Method; Female; Humans; Liver | 2007 |
Pharmacokinetics of ondansetron in patients with hepatic insufficiency.
Topics: Administration, Oral; Adult; Aged; Blood Proteins; Cross-Over Studies; Female; Half-Life; Humans; In | 1996 |
Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.
Topics: Administration, Oral; Adult; Aged; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; | 1998 |
5 other studies available for ondansetron and Liver Diseases
| Article | Year |
|---|---|
Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease.
Topics: Age Factors; Animals; Antiemetics; Cat Diseases; Cats; Female; Injections, Subcutaneous; Liver Disea | 2016 |
Ondansetron attenuates hepatic injury via p38 MAPK-dependent pathway in a rat haemorrhagic shock model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemokine CXCL1; Chemokine CXCL2; Cytoki | 2011 |
Personal view: a potential novel treatment for fatigue complicating chronic liver disease--how should its efficacy be evaluated?
Topics: Fatigue; Hepatitis C; Humans; Liver Cirrhosis, Biliary; Liver Diseases; Ondansetron; Randomized Cont | 2006 |
Development of an in vitro hepatotoxicity assay for assessing the effects of chronic drug exposure.
Topics: Acetaminophen; Amitriptyline; Cell Line; Cells, Cultured; Chemical and Drug Induced Liver Injury; Hu | 1993 |
The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.
Topics: Adult; Aged; Female; Half-Life; Humans; Infusions, Intravenous; Liver Diseases; Male; Middle Aged; O | 1993 |